Cytochroma making a splash with Morgan Stanley at Time Square
Estimated reading time: 5 minutes
We last caught up with Kate Cameron in July 25 and it’s been quite six months for them. From investment, regulatory change, commercial success and a birthday to celebrate, this feels like a real coming of age for Kate and her team at Cytochroma
Morgan Stanley Inclusive and sustainable Ventures Lab
Since Kate last spoke to us at RARE Revolution insider® Cytochroma was selected by theMorgan Stanley Inclusive and Sustainable Ventures Lab1as one of just 29 startups and four nonprofits chosen from more than 8,000 applications. The programme provides over 24 hours per month of world-class training delivered online and in person, including sessions with Morgan Stanley’s Entrepreneurs in Residence, access to offices in Canary Wharf, and tailored 1:1 support from specialists across sales, strategy, and investor readiness. Cytochroma also received a £250,000 investment through a convertible loan note, following extensive due diligence—positioning the company strongly for its next funding round.
Cytochroma’s 8th Birthday!
In October , Kate and her team celebrated Cytochroma’s 8th birthday. The company began during Kate’s academic career, when she entered a small business plan competition and placed second internationally. Inspired, she realised the cutting-edge research she was developing could transform drug development—their birthday marks a real milestone and coming of age.
Most of Cytochroma’s journey has been dedicated to research and development—developing novel methods for forming tiny organs, scaling manufacturing processes, and building automation that ensures consistency and efficiency. A recent collaboration with the University of Edinburgh used Cytochroma’s cell-based assay to validate a new target for fatty liver disease, demonstrating the real-world impact of the company’s technology.
Kate is deeply passionate about finding new cures and therapeutics for a wide range of diseases. She has raised over £2m in grant and equity funding to date and is planning a further investment round in 2026 to grow the team and deliver even better human-relevant models that can replace animal testing and improve the success rates of new medicines.
Regulatory change
The UK2 and FDA’s3 shift away from mandatory animal testing is driving new customers to Cytochroma with a goal to find alternatives to outdated animal testing. Now regulators are embracing technology like Cytochroma, opening the door to human-relevant systems that reflect real biology. Reducing barriers to adoption and accelerates industry demand for reliable, scalable human cell platforms that can predict safety and efficacy earlier.
Commercial success
Morgan Stanley’s investment and growing commercial interest have enabled Cytochroma to establish collaborations and commercial partnerships involving the FDA, major pharmaceutical companies, and leading scientific suppliers. These partnerships study enzyme function, high-throughput screening to assess the safety of new drugs and developing new cell types to study immune cell behaviour in disease.
As a pioneer in promoting diversity in preclinical research, Cytochroma has built the world’s largest commercially available library of diverse iPSC derived cells, providing insights into drug metabolism across male and female populations from around the world. This diversity-driven approach strengthens the predictive power of Cytochroma’s assays and supports the development of safer, more effective medicines.
To learn more about Cytochroma and its potential application to your research, visit the websitehereor contact Kate at info@cytochroma.org
Connect with Kate
References
[1] https://www.morganstanley.com/insights/articles/morgan-stanley-inclusive-sustainable-ventures-cohort-2025
[2] https://www.gov.uk/government/news/animal-testing-to-be-phased-out-faster-as-uk-unveils-roadmap-for-alternative-methods
[3] https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs0936-x
innovation spotlights the future of RARE through a technological lens. To access more innovation articles click below.